Phase II trial of NX 1207 given over 3 months in patients with benign prostatic hyperplasia.

Trial Profile

Phase II trial of NX 1207 given over 3 months in patients with benign prostatic hyperplasia.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2013

At a glance

  • Drugs Fexapotide (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors Nymox Pharmaceutical Corporation
  • Most Recent Events

    • 22 Jun 2010 Results after 48-60 months of follow-up, assessing AUA BPH Symptom Index scores, reported in a Nymox Pharmaceutical Corporation media release.
    • 26 Sep 2008 Results from this development program presented at the American Urological Association Meeting in Chicago, as reported in a Nymox media release.
    • 27 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top